HR Healthcare Realty Trust Inc Insider Trading

Director Bohjalian buys 10,000 HR shares at $18.09; holdings rise to 85.5K; stock currently $18.39 despite unprofitable full-year financials.

Thomas N Bohjalian, a director at Healthcare Realty Trust Inc, purchased 10,000 shares at $18.09 on 2026-03-06, increasing his stake to 85.5K shares (+13.2% vs pre-transaction holdings). The purchase occurs near the top of the 52-week trading range ($14.18–$18.88), with the stock 2.6% below its 52-week high. However, the company's fundamentals are concerning: it reported a net loss of $-57.7M on revenue of $297.8M in the latest quarter, with annual revenue declining 6.9% year-over-year and a markedly elevated P/E of 153.25 reflecting unprofitable operations. Among his prior five purchases at this ticker, his timing has been mixed—two of the five prior buys showed positive 90-day returns, while three showed losses ranging from -1.9% to -6.6%. The current buy price aligns with recent 30-day momentum (+11.0%) but arrives at a valuation inflection point given the company's negative earnings trajectory and weak annual growth, warranting examination of whether this purchase reflects confidence in a turnaround or routine portfolio activity.

CFO Gabbay buys first 10 shares of HR at $18.74 amid -6.9% revenue decline and $-57.7M net loss

Daniel Gabbay, EVP and CFO, purchased 10 shares at $18.74 on 2026-03-04, establishing an initial position after holding zero shares. The purchase occurs in a challenging backdrop: the company reported revenue of $297.8M (latest quarter) against a full-year net loss of $-57.7M, and annual revenue growth declined -6.9%. The stock is currently at $18.39, just 2.6% below its 52-week high of $18.88 despite the underlying operational headwinds. The modest scale (10 shares, $187.40 total value) and entry into a previously-zero position merit observation given the company's unprofitability and contracting revenue trajectory.

Director Bohjalian buys 10,000 HR shares at $16.46; holdings increase 15.3% to 75,520 shares

Bohjalian, a director of Healthcare Realty Trust, purchased 10,000 shares at $16.46 on 2025-08-13, expanding his position by 15.3% from 65,520 to 75,520 shares. The stock has since moved to $16.67 and has appreciated 4.1% over the past 30 days and 12.7% over 90 days. His prior buy at HR on 2025-05-13 delivered +1.4% in 30 days and +13.7% in 90 days, but his other four purchases at this ticker (2024-11-22 and 2024-09-04) generated negative 30-day and 90-day returns. The company remains unprofitable with full-year net income of $-157.9M and annual revenue has contracted 5.6% year-over-year, which provides material headwinds despite the director's accumulation.

Director Bohjalian bought 2,500 shares of HR at $14.71, holding 56,502 shares post-transaction. Stock down 22.5% from 52-week high; unprofitable company.

Director Thomas N Bohjalian purchased 2,500 shares at $14.71, increasing his holdings by 4.6% to 56,502 shares. The buy occurs against a backdrop of deteriorating fundamentals and price weakness: the company posted negative net income of $-44,873,000.00 over its most recent full fiscal year, annual revenue declined 5.6%, and the stock is -22.5% from its 52-week high and -8.1% over 30 days. His prior 5 purchases at HR delivered mixed results—only 1 of 5 were well-timed at the 90-day horizon, with the most recent batch of three purchases on 2024-11-22 all showing losses at both 30-day and 90-day marks (-2.6% to -4.9% at 90 days). The modest transaction size ($36,775.00) and continuation of a buying pattern despite recent poor outcomes and fundamental headwinds presents a data point for ongoing observation of insider positioning in an unprofitable REIT under price pressure.

Director Leupp buys 1,000 shares of HR at $16.85; joins 2 other insiders buying within 14 days amid unprofitable operations.

Director Jay P Leupp purchased 1,000 shares at $16.85, increasing his holdings from 32,830 to 33,830 shares, coinciding with a cluster of 2 other insider purchases within the prior 14 days. This multi-insider buying pattern emerges while Healthcare Realty Trust reported negative net income of $-93,023,000.00 in its most recent full fiscal year, despite posting quarterly revenue of $315,423,000.00 and annual revenue growth of +44.1%. The stock has declined 3.9% over 30 days and 5.9% over 90 days from current levels. The coordinated accumulation during a period of operational losses and recent price weakness warrants attention to whether insiders view current valuations as compelling or whether broader headwinds are being underestimated by the market.

Director Donald C. Wood buys 5,900 shares of HR at $16.86; 2 other insiders also bought within 14 days amid negative earnings.

Director Donald C. Wood purchased 5,900 shares of Healthcare Realty Trust Inc at $16.86 on 2024-12-19, establishing a new position worth $99,474.00. This transaction occurs within a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated or contemporaneous management conviction. However, the broader financial picture presents tension: the company reported the most recent quarter with revenue of $315,423,000.00 but a net loss of $-93,023,000.00, and was unprofitable over its most recent full fiscal year. The stock has declined 3.9% over 30 days and 5.9% over 90 days from recent highs, trading at $16.88 against a 52-week high of $18.78. The cluster buy pattern warrants observation to determine whether it reflects management's assessment of value at a depressed price point or signals other strategic considerations at the company.

Director Lyle Peter F SR purchases 10,000 shares of HR at $17.21; holdings increase 60.3% to 26.6K shares.

Lyle Peter F SR, a director at Healthcare Realty Trust Inc, purchased 10,000 shares at $17.21, a price that sits 7.7% below the 52-week high of $18.78 and near the middle of the annual trading range. This transaction increased his shareholdings by 60.3%, from 16.6K to 26.6K shares, representing a material expansion of his position. His two prior purchases at this same ticker on 2024-08-30 and 2024-08-29 both generated positive 90-day returns (+4.2% and +5.4% respectively), establishing a pattern of well-timed accumulation at HR specifically. However, the company remains unprofitable with net income of $-93.0M in its most recent full fiscal year, even as revenue grew 44.1% year-over-year to $315.4M, creating a disconnect between top-line growth and near-term profitability that warrants attention to whether this buying pattern reflects conviction in a turnaround or exposure to execution risk.

Director Bohjalian buys 7,750 shares at $17.34–$17.75 for $134,795; holdings rise to 50,002 shares (+18.3%).

Director Thomas N. Bohjalian executed 2 separate purchases totaling 7,750 shares for $134,795.00 on 2024-11-22, increasing his post-transaction holdings to 50,002 shares (a net increase of 18.3% versus his pre-transaction position of 42,252 shares). The blended average price of $17.39 is marginally above the current price of $17.30 and well below the 52-week high of $18.78 (current price is -7.9% from that high). Bohjalian's prior trades at Healthcare Realty Trust show mixed outcomes: his last two measurable 90-day periods yielded -0.1% and +2.2% respectively, with only 1 of 2 prior 90-day buys being well-timed. The company carries fundamental headwinds—latest quarter net income of $-93,023,000.00 (negative), though annual revenue growth of +44.1% shows topline expansion.

Director Bohjalian Thomas N purchased 4,000 shares of HR at $17.20 on 2024-11-22, increasing holdings to 54,002 shares.

Bohjalian purchased 4,000 shares at $17.20, expanding his position by 8.0% to 54,002 shares. The stock has declined 5.2% over the past 30 days and 7.9% from its 52-week high of $18.78, trading at $17.30 currently. At Healthcare Realty Trust, Bohjalian's same-ticker history shows mixed results: his buy on 2024-08-12 achieved 90-day returns of +2.2%, while his buy on 2024-08-20 achieved 90-day returns of -0.1%, placing his timing success at 50% on measurable outcomes. The company is unprofitable (net income of $-93.0M most recently) despite strong revenue growth of 44.1% year-over-year, signaling operational challenges that warrant monitoring given the scale of losses against a $6.1B market cap.

Director Singleton purchases 6,500 shares of HR at $18.24 (2 transactions, $118.6K) while company unprofitable; stock down from 52-week high

Director John Knox Singleton purchased 6,500 shares across two separate transactions on 2024-09-05 at $18.24/share for $118,564.26 total, raising his holdings from 50,582 to 57,082 shares (a +12.9% increase). This purchase occurred while Healthcare Realty Trust reported negative net income of $-143,780,000.00 over its most recent full fiscal year, and the current price of $17.95 sits 0.7% below the 52-week high of $18.07. Notably, Singleton's prior buy at this same ticker in August 2023 yielded negative returns at both 30-day (-2.6%) and 90-day (-13.8%) marks. The filing reflects a cluster pattern with 3 other insiders also buying within the past 14 days, suggesting coordinated director-level acquisition activity despite the company's unprofitable status and stock proximity to year-high valuations.